GlassScriptPhysician profile
Colin A Campbell
NPI 1477518132
$982.55
in general payments reported to CMS, 2019-2025
23 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $152 · 2023: $138 · 2024: $140 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $589.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.10 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Pfizer INC. | $140.49 | 2021-2025 | |
| Abbvie INC. | $109.43 | 2021-2025 | Qulipta |
| Kowa Pharmaceuticals America, INC. | $73.20 | 2021-2025 | Zoryve |
| Lilly USA, LLC | $63.84 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Horizon Therapeutics Plc | $55.72 | 2021-2022 | |
| Axsome Therapeutics, INC. | $54.05 | 2025 | Auvelity |
| Glaxosmithkline, LLC. | $46.28 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.73 | 2021-2024 | Xifaxan |
| Exact Sciences Corporation | $36.48 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $32.57 | 2021-2025 | Capvaxive, Gardasil 9 |
| Takeda Pharmaceuticals U.S.A., INC. | $26.87 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.16 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $18.16 | 2024 | Spravato |
| Astellas Pharma US INC | $16.42 | 2024 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.33 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.73 | 2025 | Rexulti |
| Seqirus USA INC | $13.30 | 2024 | Flucelvax, Fluad |
| Lundbeck LLC | $12.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.35 | 2021 | |
| My01 INC. | $11.30 | 2024 | My01 Continuous Compartmental Pressure Monitor |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.